FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus
Netherlands Gambling Sector Stalls as Black Market Share Climbs
Pennsylvania Gaming Industry Posts $602.4M in March 2026 Revenue, Up Nearly 5%
Taiwan’s Export Orders Surge the Most in 16 Years on AI Demand
Qualcomm (QCOM) Stock: Climbs on Samsung and SK hynix AI Chip Supply Talks
SENIOR IRANIAN MILITARY COMMANDER ALI ABDOLLAHI SAYS IRAN’S ARMED FORCES ARE READY TO DELIVER AN...
How Apple Became a $4 Trillion Company Under Tim Cook
Barclays Faces Scrutiny From UK Regulators Over Its SRT Deals
Germany's Economic Sentiment Declines Amid Rising Energy Prices
Boeing Scheduled to Report Earnings Tomorrow
Elevance Health Set to Release Q1 Earnings Report
Orcel: If We Do Not Reach Control, We Will Take a Pause (Video)
Microsoft (MSFT) Stock: Dips Before Earnings as Analysts Question Heavy AI Capex Strategy
Kevin Warsh, Trump’s Pick to Lead Fed, Faces Senate at Tricky Moment
Supreme Court Reviews F.C.C.’s Enforcement Power Against Communications Companies
Baggage Fees Are Up. Here’s How to Avoid Them.
Will S&P 500 Open Up Or Down On April 21?
Refinitiv to delete profiles of politicians’ grandchildren after lawsuit
Three Ships Including an Iranian Vessel Cross Hormuz Strait
Genting Casino Launches Royal Ascot VIP Experience Promotion for Online Players
AMD (AMD) Stock: Pulls Back From Record High as Analysts Raise Price Targets on AI CPU Boom
Even Without Internet Access, Prisoners Are Trying to Benefit From A.I.
Tesla Q1 2026 Earnings Preview: Key Events From The Past Three Months
This Earth Day, let's celebrate that Canada's air quality is the cleanest it's been in 50 years
Alternative Views with Theta’s Ruud Smets
TikTok Makes Americans Want Chinese EVs They Can’t Have
In Full: UniCredit's Orcel on His Pursuit of Commerzbank (Video)
Brazilian Officials Push Regulatory Reform Over Gambling Prohibition Amid National Debt Crisis
Bally’s Intralot Eyes £225M Deal to Acquire Struggling Evoke Gaming Group
Romania’s ONJN Announces €5 Million Program to Combat Gambling Addiction
Euro Attracts Bullish Options Buyers as Currency Goes Off Script
Guindos Says ECB Needs to Be Prudent, Keep a Cool Head on Rates
India’s Central Bank Warns of Persistent Inflation as Mideast Conflict Drags On
Intel (INTC) Stock: Pulls Back From 25-Year High Ahead of AI-Driven Earnings Test
Morgan Stanley expects positive market reaction for UK power stocks following government reforms
Avanza sinks 6% as Danish expansion costs overshadow record Q1 profit
Spain’s trade deficit narrows 24% in Jan-Feb from same period a year ago
US dollar edges higher as Iran ceasefire deadline approaches
UK employers turn cautious after start of Iran war
Hims & Hers (HIMS) Stock: Extends Rally on FDA Peptide Optimism and Subscriber Growth
Bawag Plans Dividend Limit, SRTs to Help Fund Irish Deal
Indian Wind Turbine Giant Says Nation Set to Meet 2030 Target
Apple’s next chief John Ternus faces defining AI moment
Apple (AAPL) Shares Decline Following Tim Cook’s CEO Departure Announcement
Amazon (AMZN) Stock Surges on Massive $125 Billion Anthropic AI Deal
BOJ warns prolonged Mideast tensions could raise costs, corporate defaults
U.S.-Iran ceasefire deadline; Warsh confirmation hearings - what’s moving markets
Broadcom (AVGO) Stock: Climbs Toward $2 Trillion Milestone Amid AI Chip Competition Concerns
Iranian Tanker Enters Territorial Waters with Navy Support
Vertex Pharmaceuticals Expands Cystic Fibrosis Treatment Options and Advances Kidney Drug Application
Vertex Pharmaceuticals has received FDA approval to expand the use of its cystic fibrosis therapies, which will now be available to a larger group of patients. This approval marks a significant step in addressing the needs of individuals affected by this genetic disorder.
In addition to the cystic fibrosis expansion, Vertex has submitted a priority Biologics License Application to the FDA for its drug povetacicept, aimed at treating IgA nephropathy, a kidney disease. This submission highlights the company's commitment to addressing critical health challenges in both respiratory and kidney diseases.
These recent developments underscore Vertex's focus on areas with high unmet medical needs, potentially improving treatment options for patients suffering from these conditions. The company's stock is attracting attention as it navigates these important regulatory milestones.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News